2026/2058

Part A: Policies

1. Any current commissioning policy or clinical threshold that restricts, requires prior approval for, or sets criteria for procedures or treatments involving a medical device. This includes your Evidence-Based Interventions or Procedures of Limited Clinical Value policy and any prior approval list.
2. Any current formulary, preferred product list or supply scheme for devices and appliances, including wound care, stoma, continence, compression, blood glucose monitoring (including CGM) and any other device categories you cover.
3. For each item in 1 and 2, its approval date and next review date.

Part B: Decision making

4. The name of the committee or group that approves the items in Part A, and its terms of reference.
5. That committee’s meeting dates from 1 April 2026 to 31 March 2027.
6. The process a supplier or clinician must follow to submit a product for formulary consideration, including any submission form and evidence requirements.
7. Whether device and appliance supply in your area is through FP10 prescribing, a direct supply or off-prescription scheme, or both. If a scheme is in place, the provider’s name and the contract end date.

1. Please note that from 1^st July 2022 a new operating model was introduced for treatments covered by a GM PLCV Commissioning Statement. This means that interventions which were either Individual Prior Approval (IPA) or Monitored Approval (MA) treatments became ‘permissible’ treatments. Therefore, where a patient meets the criteria in a GM PLCV Commissioning Statement there is no longer a requirement to obtain prior approval from the GM IFR Service (formerly the GM EUR Team) before referring or treating the patient, provided that the patient meets the criteria contained in the GM Policy Statement for the required intervention.  Here is a link to NHS GM’s PLCV Commissioning Statements and Evidence-Based Interventions.

2. Where there is a GM formulary and preferred product lists for devices and appliances this is publicly available via the GMMMG website. See Medicines and Devices Recommendations – GMMMG. The below documents are relevant to this request.

• https://gmmmg.nhs.uk/wp-content/uploads/2026/05/NHS-GM-Safety-Pen-Needles-and-Lancets-Position-Statement-V1.0-FINAL.pd
• GM-CGM-Prescribing-Eligibility-Oct-25-FINAL-without-covers.pdf
• NTS recommendation PICO® dressings for difficult to manage wounds

3. Currently all development and review work of the GM PLCV Commissioning Statements is on hold due to the organisational changes that are taking place. NHS GM usually aims to review all new or existing GM PLCV commissioning statements every five years from the date of the last review, unless new evidence or technologies emerge, which would change the current commissioning stance. In which case, the review date of the PLCV commissioning statement may be brought forward.

For GMMMG formulary and preferred product lists for devices and appliances, the approval date for each published document is included within the document. NHS Greater Manchester reviews the GMMMG formulary recommendations, position statements and commissioning guidance on an ongoing basis and updates documents when a review is considered necessary due to changes in evidence, national guidance, safety information, commissioning arrangements or local priorities. As a result, published review dates should be considered indicative only and may not reflect the timing of future reviews.

4. The GM Procedures of Low Clinical Value Steering Group is not a decision-making group; they make recommendations to NHS GM on what the criteria should be for each commissioning statement. This recommendation then goes through the organisation’s governance process seeking approval implement.

5. The GM Procedures of Low Clinical Value Steering Group last met of 8^th April 26. Meetings have been stood down to allow changes within the organisation to take place, which are still ongoing. The GM PLCV Commissioning Statements go through the following governance group’s/committees 1) Clinical Policy Aduit and Standards (CPAS) – to seek approval to go through the governance process, Clinical Effectiveness and Governance (CEG) – to endorse the policy and the Strategic Commissioning Committee for ratification. Further dates have been provided within the attached and the terms of reference for the Strategic Commissioning Committee (SCC).

6. The process for GMMMG formulary applications can be found at this link: https://gmmmg.nhs.uk/joint-formulary/submissions/

NHS GM does not hold information related to this question.

**A word document was sent to the requester with this response.  If you require a copy of the full response, together with the attachments, please contact NHS GM’s FOI team – nhsgm.foi@nhs.net **

**PDF documents were sent to the requester with this response.  If you require a copy of the full response, together with the attachments, please contact NHS GM’s FOI team – nhsgm.foi@nhs.net **